Please use this identifier to cite or link to this item:
|Title:||Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.|
|Abstract:||New treatments with novel mechanisms of action and non-overlapping toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to treatment of physician's choice (TPC) demonstrated its clinical activity. We now present detailed safety data from the BEACON trial.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos|
Files in This Item:
|PMC4938835.pdf||857.62 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.